• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai, July 19 ABL Biotechnologies Ltd, a Chennai-based marine biotechnology research and development company, has signed an MoU with Christian Medical College, Vellore for joint research in tuberculosis, cancer, cardio vascular diseases and nanotechnology-based therapy.

The company’s Chairman and Managing Director, Mr. K.O. Issac, said ABL Biotech was also planning to expand the reach of Invia Health, its pharmaceutical division launched last year The company will first take Invia Health to Kerala by August and later Andhra Pradesh, Karnataka and Orissa. “This expansion will see the company placing products in cardio-diabetic segment including medicines for the management of heart failure,” said Mr P.S. Ganeshan, President, Invia Health.

The products identified for launch this year include Glimod M, Glysense and Eunerv G. On the BSE today, ABL Biotech’s share price closed at Rs 97.10, up Re 0.30 over previous close.

The company’s turnover in 2006-07 was Rs 12.50 crore and net profit Rs 2.15 crore. EPS was Rs 5.24.

More Stories on : Alliances & Joint Ventures | Health | Research & Development | Tamil Nadu

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
RNRL seeks changes in gas supply pact with Reliance

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line